EMA Authorised: Klisyri (tirbanibulin) — Almirall, S.A.

View source ↗

Summary

The European Medicines Agency authorised Klisyri (tirbanibulin) for actinic keratosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• KLISYRI (tirbanibulin)

Snippet

Status: Authorised. Therapeutic area: Keratosis, Actinic. MAH: Almirall, S.A.. Decision date: 12/02/2026